ClinicalTrials.gg
RecruitingNCT06898684MOVEUpdated Dec 16, 2025

Medulloblastoma Online Video-based Exercise Pilot Study

An interventional study of Exercise in Medulloblastoma, Childhood, sponsored by Aron Onerup. Recruiting at 2 sites in 2 countries. Open to participants aged 3 Years to 18 Years. Per ClinicalTrials.gov, last updated 2025-12-16.

Sponsored by Aron Onerup · Not applicable, Interventional, and Supportive care

How we know

From the registry’s dates

  • Started Dec 2025; still recruiting 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
15
Allocation
Not applicable
Ages
3 Years to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 15 studies in Medulloblastoma with a site in Germany — 3 open to participants now, 5 under way, 1 of them phase 3. Medulloblastoma · Germany.

Planned enrollment
9th of 11
15 · median 33
Started
2025
the only one that year
No phase
Only one
of the 15
Registered
15th of 15
by date
Lead sponsor
1 of 15
Aron Onerup

Among the 15 studies in Medulloblastoma with a site in Germany, this one is the 9th largest by planned enrollment of the 11 interventional ones that give a count, is the only one that started in 2025, is the only one with no phase, and was the 15th registered.

Medulloblastoma

317 studies on the registry are indexed under Medulloblastoma; 52 are open to participants now.

Browse Medulloblastoma studies →

Open to participants now

3 of the 15 studies in Medulloblastoma with a site in Germany are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 38 Medulloblastoma studies recruiting now, 4 (11%) set no upper age limit and 32 (84%) stop at 75 or younger; 35 take children under 18; 1 takes healthy volunteers.

This study: 3 Years to 18 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Medulloblastoma with a site in Germany, or all of them as a file.
02

Study summary

In this study, the investigators test whether it is possible to deliver an exercise intervention via video meetings to children and adolescents who have completed therapy for medulloblastoma. The exercise sessions will be individualized and offered three times weekly during 12 weeks.

Read the detailed description

Tumors of the central nervous system (CNS) represent 25-30% of all cases of pediatric cancer in Sweden. The survival for children with a brain tumor has improved over the last years. The 5-year overall survival rate is now 70%, resulting in a growing number or survivors every year. Malignant brain tumors typically have a poor prognosis, and curative treatment usually requires a combination of neurosurgery, chemotherapy and/or radiotherapy. For the survivors, the cure often comes at the cost of long-term side effects. Finding effective ways to mitigate the long-term side effects after childhood brain tumor is important, since they can severely impact the survivors´ daily life.

There is growing evidence that physical exercise is beneficial to cognition and improves cardiorespiratory fitness and motor function. It appears to be important that interventions start early, within 1-2 years after radiotherapy. For this to be feasible in international multicenter trials, the intervention and outcome assessments will need to be delivered remotely. Whether this is feasible in children treated for medulloblastoma is not known.

The investigators will perform a pilot study to provide pivotal information on whether exercise training can be remotely delivered in the home environment in children treated for medulloblastoma. This will take exercise training from an interesting research concept into a scalable intervention that can be offered regardless of geographic location of the patient. The study will further define the validity and feasibility of in-home outcome assessments of cardiorespiratory, muscular fitness and motor function in children treated for medulloblastoma. If shown feasible, this will work as a proof-of-concept and lead the way for including physical activity intervention in other childhood cancer treatment protocols as well. The results from this study will also enable the researchers to proceed in the planning of the first exercise intervention to be included upfront in an international childhood cancer treatment protocol, the upcoming Pan-European treatment protocol for standard-risk medulloblastoma in children (SIOP-MB6).

03

Conditions studied

  • Medulloblastoma, Childhood

Keywords

  • exercise
  • rehabilitation
  • medulloblastoma
04

Who can participate

Ages eligible
3 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria: Completed therapy for medulloblastoma, including craniospinal radiation therapy, within 36 months before study entry.

-

Exclusion Criteria: Inability to walk without support. Progressive disease.

-

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
15 participants (estimated)

Study arms

  • Experimental
    Exercise

    Video-supervised exercise, offered three times per week for 12 weeks, followed by behavioral support towards incorporating physical activity into daily life for an additional 12 weeks.

    Behavioral: Exercise

Interventions

  • BehavioralExercise

    Moderate-high intensity exercise, with three sessions per week during 12 weeks. Includes both aerobic and resistance training and will also include exercises that strengthen coordination and balance.

06

What researchers measure

Primary outcomes

  1. Feasibility of the remote assessment and a digitally delivered exercise intervention

    The researchers will test the feasibility of delivering the exercise intervention via video, defined as: 1. Adherence to the intervention by number of completed intervention sessions Acceptable level: ≥70% adherence at 6 months. 2. Data collection - feasibility of outcome measures Criteria: ≥ 90% of video-based measurements can be conducted according to protocol. ≥ 80% of PROM assessments can be completed as planned. 3. Safety Documentation of adverse events (all occurring and documented adverse events associated with the intervention will be recorded in accordance with the Common Terminology Criteria for Adverse Events (CTCAE), version 5.0.). 4. Acceptance and perceived usefulness Criterion: Qualitative analysis of interviews shows that the intervention is perceived as meaningful, feasible, and not too burdensome. 5. Technical aspects Criterion: ≥ 90% of participants can complete video sessions without major technical problems, beginning after the first three sessions.

    Time frame: From enrollment to the end of exercise at 12 weeks and then for prolonged support for another 12 weeks.

Secondary outcomes

  1. Handgrip strength

    Measured with a hand dynamometer

    Time frame: Change from baseline, until 3 and 12 months.

  2. Physical activity

    Activity counts per day, registered with accelerometry (Fibion Sens)

    Time frame: Change from baseline, until 1.5, 3, 6, and 12 months.

  3. Patient-reported quality of life

    Measured with Patient-Reported Outcomes Measurement Information System (PROMIS)-25.

    Time frame: Change from baseline, until 3 and 12 months.

  4. Motor function

    Assessed with the brief ataxia rating scale (BARS), higher numbers indicate worse outcomes.

    Time frame: Change from baseline, until 3 and 12 months.

  5. Cardiorespiratory fitness

    Assessed with the 3-min step in place test

    Time frame: Change from baseline, until 3 and 12 months.

  6. Epigenetic age acceleration

    Epigenetic age will be determined from DNA methylation analyses of DNA extracted from saliva samples.

    Time frame: Change from baseline, until 3 and 12 months.

  7. Feasibility of the outcome measures

    The researchers will develop the outcome assessments battery by removing outcome assessments that are not feasible through video.

    Time frame: 12 weeks

  8. Cognitive function

    Patient-Reported Outcomes Measurement Information System (PROMIS) cognitive function 7a.

    Time frame: Change from baseline to 12 weeks and 12 months.

  9. Lower limb strength

    We will assess lower limb strength with the five repetition sit-to-stand test, assessed with the number of seconds to perform the test. The same chair will be used across all time points.

    Time frame: Change from baseline until 3 and 12 months.

07

Study locations

1 of 2 sites recruiting
  • Technical University Munich
    München, Germany
    Not yet recruiting
  • Queen Silvia C hildren´s Hospital
    Gothenburg, Sweden
    Recruiting
    • Aron Onerup, MD, PhD · Contactaron.onerup@gu.se · +46313421000
    • Aron Onerup · Principal investigator
08

References and documents

Individual participant data

Plan to share: No — This is a small feasibility study and will not generate data that will be meaningful to share.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Dec 2025 (actual). Primary completion is estimated for Dec 2026, 12 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 13, 2025
First posted
Mar 27, 2025
StartActual
Dec 9, 2025
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2027
Last update
Dec 16, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 16, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06898684
Lead sponsor
Aron Onerup
Responsible party
Aron Onerup (Principal investigator, Vastra Gotaland Region) — Sponsor-investigator
First posted
Mar 27, 2025
Start date
Dec 9, 2025
Primary completion
Dec 2026 (estimated)
Completion
Dec 2027 (estimated)
Last update
Dec 16, 2025

Study contacts

Aron Onerup, MD, PhD
Contact
aron.onerup@gu.se
+46766185619

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion